Indivior Pharmaceuticals Inc (INDV) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Indivior Pharmaceuticals Inc   (NASDAQ: INDV)


Indivior Pharmaceuticals Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Indivior Pharmaceuticals Inc's ROI in the third quarter of 2026?
Indivior Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 114.32 % in its third quarter of 2026, this is above INDV's average return on investment of 28.02%.
Indivior Pharmaceuticals Inc invested over the 12 months ending in its third quarter of 2026 $395 million

ROI has improved compared to 72.14% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 20 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 74 to 127.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM -28.85 % -11.08 % 232.75 % 2693.55 % -
Y / Y Net Income Change TTM 252.34 % 229.63 % 180 % 388.37 % 481.82 %
Investment (TTM) in Millions 31 365 404 778 427
Return On Investment (TTM) 114.32 % 72.14 % 37.87 % 32.33 % 23.08 %
INDV's Overall Ranking # 127 # 74 # 65 # 61 #
Seq. Investment Change TTM -20.06 % -25.85 % 2.46 % 17.13 % -0.09 %
Seq. Net Income Change TTM 26.69 % 41.27 % 20 % 64.06 % 18.52 %
Net Income (TTM) in Millions 451 356 252 210 128

INDV Company Profile >> Back to INDV Roi Comparisons >> See Annual INDV Return On Investment



Return On Investment INDV's Ranking
Within: No.
Industry # 9
Sector # 21
Overall # 127

Return On Investment Statistics
High Average Low
68.79 %
28.02 %
-3.25 %
(Jun 30 2026)   (Mar 31 2025)







Financial Statements
Indivior Pharmaceuticals Inc's III. Quarter Investments $ 31 Millions INDV's Balance sheet
Indivior Pharmaceuticals Inc's III. Quarter Income $ 137 Millions Quarterly INDV's Income Statement
INDV's Income by Division See INDV's Income by Division


INDV Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023

Total Investments in Millions 291 398 429 0 0
Y / Y Investment Growth -26.88 % -7.23 % - - -
Net Income in Millions 210 2 2 0 0
Y / Y Net Income Growth 10400 % 0 % - - -
Annual Return On Investment 72.16 % 0.5 % 0.47 % - -


Annual Roi Comment
In the fiscal year 2025 ROI improved to 72.16 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
INDV's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for INDV's Competitors
Subscribers only: Roi for Indivior Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for INDV's Customers

Other Ratios
INDV's Roa INDV's Inventory Turnover Ratio INDV's Growth Rates INDV's Dividend Statistics
INDV's Profitability Ratios INDV's Asset Turnover Ratio INDV's Dividend Growth
INDV's Roe INDV's Valuation Ratios INDV's Financial Strength Ratios INDV's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Vor Biopharma Inc   293.36 %
Indivior Pharmaceuticals Inc   108.22 %
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %

Date modified: 2026-10-30T13:13:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.